# Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors

> **NCT06932094** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 256 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QLS5132

## Key facts

- **NCT ID:** NCT06932094
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2027-05
- **Final completion:** 2028-02
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932094, "Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06932094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*